Cargando…
Structure–Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors
[Image: see text] EPAC proteins are therapeutic targets for the potential treatment of cardiac hypertrophy and cancer metastasis. Several laboratories use a tetrahydroquinoline analog, CE3F4, to dissect the role of EPAC1 in various disease states. Here, we report SAR studies with tetrahydroquinoline...
Autores principales: | Sonawane, Yogesh A., Zhu, Yingmin, Garrison, Jered C., Ezell, Edward L., Zahid, Muhammad, Cheng, Xiaodong, Natarajan, Amarnath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774307/ https://www.ncbi.nlm.nih.gov/pubmed/29375750 http://dx.doi.org/10.1021/acsmedchemlett.7b00358 |
Ejemplares similares
-
Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective
por: Ahmed, Alveena, et al.
Publicado: (2019) -
Biochemical and Pharmacological Characterizations of ESI-09 Based EPAC Inhibitors: Defining the ESI-09 “Therapeutic Window”
por: Zhu, Yingmin, et al.
Publicado: (2015) -
Epac-Inhibitors: Facts and Artefacts
por: Rehmann, Holger
Publicado: (2013) -
Structure-Guided Design of Selective Epac1 and Epac2 Agonists
por: Schwede, Frank, et al.
Publicado: (2015) -
Cyclin Dependent
Kinase 9 Inhibitors for Cancer Therapy: Miniperspective
por: Sonawane, Yogesh A., et al.
Publicado: (2016)